Compounds > myxovirescin a
Page last updated: 2024-12-11

myxovirescin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

myxovirescin A: from Myxococcus virescens; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6450484
CHEMBL ID442007
MeSH IDM0112173

Synonyms (5)

Synonym
CHEMBL442007
(2s,6s,8s,9r,12z,14e,16r,25r,27s)-16-ethyl-6,8,9-trihydroxy-12-(methoxymethyl)-25,27-dimethyl-2-propyl-1-oxa-4-azacyclooctacosa-12,14-diene-3,20,28-trione
myxovirescin a1
myxovirescin a
85279-97-6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID72262Minimum inhibitory concentration against Fusobacterium sp.(ATCC 74714) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID160995Minimum inhibitory concentration against Porphyromonas canoris (ATCC NCTC 12836) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID205555Minimum inhibitory concentration against Staphylococcus aureus (ATCC NCTC 6571) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID155935Minimum inhibitory concentration against Pasteurella sp.(ATCC 67535) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID155936Minimum inhibitory concentration against Pasteurella sp.(ATCC 67777) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID69483Minimum inhibitory concentration against Escherichia coli (ATCC NCTC 6571) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID54152Minimum inhibitory concentration against Corynebacterium sp. (ATCC 68984) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID41420Minimum inhibitory concentration against Bacteroides oralis (ATCC 72708) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID41423Minimum inhibitory concentration against Bacteroides ovatus (ATCC 66640) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID160994Minimum inhibitory concentration against Porphyromonas canoris (ATCC NCTC 12835) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID41557Minimum inhibitory concentration against Bacteroides uniformis (ATCC 62723) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID72249Minimum inhibitory concentration against Fusobacterium mortiferum (ATCC 63425) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID30571Minimum inhibitory concentration against Actinomyces sp.(ATCC 70710) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID160998Minimum inhibitory concentration against Porphyromonas gingivalis sp.(ATCC D23C) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID1324804Antibacterial activity against Escherichia coli by agar dilution method2016Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24
Drug discovery strategies to outer membrane targets in Gram-negative pathogens.
AID155937Minimum inhibitory concentration against Pasteurella sp.(ATCC 69527) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID155938Minimum inhibitory concentration against Pasteurella sp.(ATCC 71886) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID160394Minimum inhibitory concentration against Propionibacterium sp.(ATCC 72661) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID155780Minimum inhibitory concentration against Pasteurella multocida (ATCC 63560) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID155779Minimum inhibitory concentration against Pasteurella multocida (ATCC 61096) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID1064479Antibacterial activity against Escherichia coli NCTC 10418 assessed as growth inhibition2014Bioorganic & medicinal chemistry letters, Jan-15, Volume: 24, Issue:2
New natural products as new leads for antibacterial drug discovery.
AID41104Minimum inhibitory concentration against Bacteroides bivus (ATCC 64362) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID41106Minimum inhibitory concentration against Bacteroides buccae (ATCC 67792) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID30565Minimum inhibitory concentration against Actinomyces meyeri (ATCC 61789) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
AID41108Minimum inhibitory concentration against Bacteroides capillosus (ATCC 60802) using agar method2003Bioorganic & medicinal chemistry letters, Feb-10, Volume: 13, Issue:3
Myxovirescin analogues via macrocyclic ring-closing metathesis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's0 (0.00)18.2507
2000's8 (53.33)29.6817
2010's5 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.36 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (26.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-hydroxy-3-methylglutaryl-coenzyme a
3-hydroxy-3-methylglutaryl-coenzyme A: RN given refers to cpd without isomeric designation. 3-hydroxy-3-methylglutaryl-CoA : An alpha,omega dicarboxyacyl-CoA that results from the formal condensation of the thiol group of coenzyme A with one of the carboxy groups of 3-hydroxy-3-methylglutaric acid.. (3S)-3-hydroxy-3-methylglutaryl-CoA : A 3-hydroxy-3-methylglutaryl-CoA where the 3-hydroxy-3-methylglutaryl component has (S)-configuration.		2.03103-hydroxy-3-methylglutaryl-CoA;
3-hydroxy fatty acyl-CoA		human metabolite;
mouse metabolite
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		3.1110epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
soraphen a
[no description available]		3.1110cyclic hemiketal;
ether;
macrolide;
olefinic compound		bacterial metabolite;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
teratogenic agent
chir 090
CHIR 090: structure in first source. CHIR-090 : An L-threonine derivative obtained by formal condensation of the carboxy group of 4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)benzoic acid with the amino group of N-hydroxy-L-threoninamide.		3.2310acetylenic compound;
benzamides;
hydroxamic acid;
L-threonine derivative;
morpholines		antimicrobial agent;
EC 3.5.1.108 (UDP-3-O-acyl-N-acetylglucosamine deacetylase) inhibitor;
lipopolysaccharide biosynthesis inhibitor
arylomycin a-c16
[no description available]		3.1910
kibdelomycin
kibdelomycin: an antibiotic that inhibits both gyrase and DNA topoisomerase IV; isolated from Kibdelosporangium; structure in first source		3.1910
corallopyronin a
corallopyronin A: structure in first source		2.0610
ConditionIndicatedRelationship StrengthStudiesTrials